Further research is urgently needed to investigate the relationship between neoadjuvant trastuzumab plus chemotherapy and the immune microenvironment of HER2-positive breast cancer and whether this treatment can affect the immune microenvironment of local antitumor. Here, ERBB2 is linked to breast carcinoma.